Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation.
Neurology
; 81(13): 1176-8, 2013 Sep 24.
Article
en En
| MEDLINE
| ID: mdl-23946313
ABSTRACT
We previously reported clinical improvement, increase in putamen [(18)F]-dopa uptake on PET imaging, and neuropathologic evidence of sprouting of dopaminergic fibers following chronic intraputaminal delivery of glial cell line-derived neurotrophic factor (GDNF) in idiopathic Parkinson disease (PD).(1-3) We now provide clinical and PET evidence of persistent efficacy lasting for at least 3 years following cessation of GDNF infusion in a patient with PD. This is a single-case observational study, providing Class IV evidence.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Enfermedad de Parkinson
/
Putamen
/
Factor Neurotrófico Derivado de la Línea Celular Glial
/
Antiparkinsonianos
Tipo de estudio:
Observational_studies
Límite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Neurology
Año:
2013
Tipo del documento:
Article
País de afiliación:
Reino Unido